PREVALENCE OF METABOLIC DISTURBANCES IN PATIENTS USING ANTIPSYCHOTIC MEDICATION:

使用抗精神病药物的患者中代谢紊乱的患病率：

• 批准号: 7376079
• 负责人: MICHAEL SMITH
• 金额: $ 4.43万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376079
• 关键词: PREVALENCE; METABOLIC; DISTURBANCES; PATIENTS; USING

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The newer antipsychotic medications known as the atypical antipsychotic medications have helped to alleviate symptoms of psychosis and have become widely used in patients with schizophrenia and other psychotic disorders. However, accumulating evidence over the past years suggests that metabolic disturbances (conditions such as diabetes and high cholesterol or high fat content) associated with the atypical antipsychotics may be common. Since patients with psychosis also tend to be the ones with increased risk factors for cardiovascular disease such as smoking and sedentary lifestyle, this pilot study hopes to identify individuals on antiphysotic medications who have these metabolic abnormalities and try to understand why and how they may be more at risk. Participants in the study will undergo clinical history review, a physical measurement of blood pressure, weight, height, waist and hip circumference, and a series of three blood draws will be done while participants are in a fasting state (that is, not food intake after midnight the night prior to testing) to determine the body's level of glucose, insulin and fat as well as a specific test known as the glucose tolerance test to determine their body's ability to use glucose.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。新的抗精神病药物被称为非典型抗精神病药物，有助于缓解精神病症状，并已被广泛用于精神分裂症和其他精神障碍患者。然而，过去几年积累的证据表明，与非典型抗精神病药物相关的代谢障碍(如糖尿病和高胆固醇或高脂肪含量)可能是常见的。由于精神病患者也往往是吸烟和久坐不动的生活方式等心血管疾病风险因素增加的人，这项试点研究希望找出服用抗麻药药物的人有这些代谢异常，并试图了解他们可能面临更大风险的原因和方式。这项研究的参与者将接受临床病史回顾，对血压、体重、身高、腰围和臀围进行身体测量，并在参与者处于禁食状态(即测试前一晚午夜后不进食)时进行一系列三次抽血，以确定身体的葡萄糖、胰岛素和脂肪水平，以及一项被称为葡萄糖耐量测试的特定测试，以确定他们身体利用葡萄糖的能力。